Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Rating of “Buy” by Analysts

Revolution Medicines, Inc. (NASDAQ:RVMD) has received a consensus rating of “Buy” from the twenty-one research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $111.3529.

Several analysts have issued reports on RVMD shares. Jefferies Financial Group started coverage on shares of Revolution Medicines in a research report on Monday, March 16th. They issued a “buy” rating on the stock. Stifel Nicolaus restated a “buy” rating on shares of Revolution Medicines in a research report on Monday, April 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research note on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Revolution Medicines in a research note on Wednesday, April 22nd. Finally, Piper Sandler increased their target price on shares of Revolution Medicines to $172.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th.

Revolution Medicines Stock Up 2.3%

Revolution Medicines stock opened at $153.73 on Friday. The firm has a market cap of $32.68 billion, a PE ratio of -21.74 and a beta of 1.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.80 and a current ratio of 6.80. The firm’s 50 day moving average price is $122.71 and its two-hundred day moving average price is $100.85. Revolution Medicines has a twelve month low of $34.00 and a twelve month high of $155.70.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter in the previous year, the business posted ($1.13) EPS. On average, research analysts predict that Revolution Medicines will post -7.75 EPS for the current fiscal year.

Insider Buying and Selling at Revolution Medicines

In other news, insider Xiaolin Wang sold 2,010 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $199,954.80. Following the sale, the insider directly owned 116,063 shares in the company, valued at approximately $11,545,947.24. The trade was a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Stephen Michael Kelsey sold 4,302 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $427,962.96. Following the sale, the insider owned 295,398 shares in the company, valued at approximately $29,386,193.04. This represents a 1.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 184,592 shares of company stock valued at $24,499,532 in the last quarter. 8.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Revolution Medicines

Several institutional investors have recently made changes to their positions in the business. Meeder Advisory Services Inc. grew its stake in shares of Revolution Medicines by 3.0% in the 1st quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company’s stock valued at $401,000 after purchasing an additional 120 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Revolution Medicines by 1.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company’s stock worth $802,000 after buying an additional 125 shares during the period. Deutsche Bank AG lifted its position in shares of Revolution Medicines by 0.4% during the 4th quarter. Deutsche Bank AG now owns 32,217 shares of the company’s stock worth $2,566,000 after buying an additional 130 shares during the period. Signaturefd LLC lifted its position in shares of Revolution Medicines by 33.1% during the 4th quarter. Signaturefd LLC now owns 656 shares of the company’s stock worth $52,000 after buying an additional 163 shares during the period. Finally, Allworth Financial LP lifted its holdings in shares of Revolution Medicines by 57.2% during the fourth quarter. Allworth Financial LP now owns 577 shares of the company’s stock valued at $46,000 after acquiring an additional 210 shares during the period. 94.34% of the stock is currently owned by institutional investors and hedge funds.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.